CHF-6001
- Generic Name
- CHF-6001
- Drug Type
- Small Molecule
- Chemical Formula
- C30H30Cl2F2N2O8S
- CAS Number
- 1239278-59-1
- Unique Ingredient Identifier
- 0984EU6E2F
- Background
CHF6001 has been used in trials studying the treatment of Asthma and Chronic Obstructive Pulmonary Disease.
A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 50
- Registration Number
- NCT06900816
- Locations
- 🇧🇬
Medical Centre Comac Medical Ltd., Sofia, Krasno Selo District, Bulgaria
Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 24
- Registration Number
- NCT06892756
- Locations
- 🇧🇬
Medical Centre Comac Medical Ltd, Sofia, Bulgaria
Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 24
- Registration Number
- NCT06395610
- Locations
- 🇧🇬
MC Comac Medical Ltd., Sofia, Bulgaria
Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 44
- Registration Number
- NCT05373953
- Locations
- 🇧🇬
MC Comac Medical Ltd., Sofia, Bulgaria
Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)COPD
- Interventions
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 8
- Registration Number
- NCT04756960
- Locations
- 🇬🇧
Covance - Clinical Research Unit, Leeds, United Kingdom
Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 24
- Registration Number
- NCT04739774
- Locations
- 🇧🇪
SGS Life Sciences - Clinical Pharmacology Unit Antwerpen, Antwerp, Belgium
A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1130
- Registration Number
- NCT02986321
Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 55
- Registration Number
- NCT01730404
- Locations
- 🇮🇪
Celerion, Belfast, Ireland
🇬🇧Medicines Evaluation Unit Ltd, Manchester, United Kingdom
🇬🇧Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 36
- Registration Number
- NCT01689571
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
🇬🇧Respiratory Clinical Trials, London, United Kingdom
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.